department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Clobetasol Propionate · pharmadog

pharmadog
drugs
Clobetasol Propionate

drug

patient view →

Clobetasol Propionate Teva

Marketedupdated 2mo ago

by Teva Pharmaceuticals USA Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 12 investigational indications.

indications

investigational

Psoriasis

all catalysts(1)

approval · 1

News(0)

no news has mentioned this drug yet

brand

Clobetasol Propionate

generic

clobetasol propionate

MOA

Glucocorticoid receptor agonist

indication

Atopic Dermatitis (Atopic Eczema)

phase

marketed

CLOBETASOL PROPIONATE — FDA approval

Clobetasol Propionate Teva

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 4, 2027

240 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

May 9, 2036formulationUS 10588913
May 9, 2036formulationUS 11376262
Mar 11, 2035formulationUS 9855334
Aug 31, 2030formulationUS 100648754.2y
Aug 31, 2030formulationUS 105889144.2y
Aug 31, 2030formulationUS 111794654.2y
Aug 31, 2030formulationUS 99562314.2y
Nov 5, 2028formulationUS 84606412.3y

FDA exclusivities (1)

Mar 4, 2027NPNP240d

🐶 often sniffed alongside

top 4

tagApproval2 co-mentions · 1 sources
drugCLOBETASOL PROPIONATE1 co-mentions · 1 sources
drugClobex1 co-mentions · 1 sources
drugDermovate1 co-mentions · 1 sources

Trials studying Clobetasol Propionate Teva

phase1A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)completedn=30
phase1A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skincompletedn=16
phase1A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgariscompletedn=24
phase1A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skincompletedn=40
phase3Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Populationrecruitingn=60